Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Drug Injury
  • About Our Firm
  • Free Case Evaluation
  • Frequently Asked Questions

Modest Results for Checkpoint Agents in Mesothelioma

September 20, 2016 By Law Offices of Thomas J. Lamb, P.A.

Two trials presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO) provide somewhat discouraging findings on checkpoint inhibitors for second-line treatment of mesothelioma.

In the largest checkpoint inhibitor study in mesothelioma to date, a Phase IB study conducted with the programmed death ligand-1 (PD-L1) inhibitor avelumab (Pfizer), the objective response rate (ORR) among the 53 patients in the study, who had unresectable pleural or peritoneal mesothelioma that had progressed after chemotherapy, was 9.4%, and 47.2% achieved stable disease (abstract 8503). The median progression-free survival was 17.1 weeks, but several responders remain on avelumab and are being followed for long-term benefit, reported Raffit Hassan, MD, the head of the thoracic and solid tumor immunotherapy section of the National Cancer Institute, in Bethesda, Md.

Although the ORR has been closer to 30% in smaller and previously reported studies with the programmed death-1 (PD-1) inhibitors pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb), the ASCO-invited discussant of the study, Tom John, MBBS, PhD, a senior investigator in thoracic oncology at the Olivia Newton-John Cancer Research Institute, in Melbourne, Australia, suggested the studies have been relatively consistent. “There is a signal for efficacy in mesothelioma, but these studies are also a reality check,” Dr. John reported. With a PD-1 inhibitor monotherapy, “most patients do not seem to benefit.”

Source: Modest Results for Checkpoint Agents in Mesothelioma


 Mesothelioma, Asbestos, and Legal Compensation: Basic Facts

Asbestos-Mesothelioma Case Evaluation Form
Free.  Confidential.  No Obligation.

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos, asbestos cancer, asbestos-related disease, mesothelioma, mesothelioma treatments

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Cases
  • Breast Implant Cases
  • Philips Breathing Devices Cases
  • GenX Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2022 · Law Offices of Thomas J. Lamb, P.A.